Helix insider converts 30,000 Class B to 30,000 BBOT common

John P. Schmid reported a corporate reorganization-driven conversion that resulted in direct ownership of 30,000 common shares of BridgeBio Oncology Therapeutics, Inc. (ticker BBOT).

Rhea-AI Filing Summary

John P. Schmid reported a corporate reorganization-driven conversion that resulted in direct ownership of 30,000 common shares of BridgeBio Oncology Therapeutics, Inc. (ticker BBOT). The Form 4 shows a transaction dated 08/11/2025 where 30,000 Helix Class B ordinary shares were recorded in connection with a business combination and domestication that converted Helix Class B to Helix Class A on a one-for-one basis and then Helix Class A to the Issuer's common stock one-for-one.

The filing states the reporting person was a director of Helix prior to the domestication and resigned effective 08/11/2025, immediately prior to the domestication. Following the reported conversion, the Form 4 lists 30,000 shares beneficially owned following the transaction, held directly.

Positive

• 30,000 common shares are reported as directly beneficially owned following the conversion, clarifying the reporting persons post-transaction stake
• The filing documents a one-for-one conversion sequence from Helix Class B to Helix Class A to issuer common stock, showing clear treatment of legacy securities

Negative

• The reporting person resigned as a director of Helix effective 08/11/2025, immediately prior to the domestication

Insights

Securities Analyst

TL;DR: Conversion raised direct holdings to 30,000 BBOT common shares; director resigned immediately before domestication.

The Form 4 documents a mechanical ownership change tied to the business combination and domestication described in the explanation section. The reporting person ended up with 30,000 common shares following a one-for-one conversion sequence from Helix Class B to Helix Class A to issuer common stock. The transaction is reported with transaction code M (1) and shows direct beneficial ownership of 30,000 shares after the event. No cash purchase price is reported for the conversion in the filing.

Corporate Governance Expert

TL;DR: Director resignation concurrent with share conversion; ownership clarified but governance change is noted.

The document confirms that the reporting person resigned as a director of Helix effective the same date as the domestication and conversion transactions. The filing therefore records both an ownership reconciliation and a corporate governance event: a resignation and the conversion of legacy Class B shares into 30,000 common shares of the successor issuer. The filing does not provide additional governance details such as replacement director information or board composition after the resignation.

Insider Trade Summary

30,000 shares exercised/converted

Exercise 2 txns

Insider Schmid John P.

Role Insider

Type	Security	Shares	Price	Value
Exercise	Class B ordinary shares	30,000	$0.00	$0.00
Exercise	Common Stock	30,000	$0.00	$0.00

Holdings After Transaction: Class B ordinary shares — 0 contracts (Direct); Common Stock — 30,000 shares (Direct)

Footnotes (1)

1. F1. In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did John P. Schmid report on the Form 4 for HLXB/BBOT?

The Form 4 reports a conversion-related transaction dated 08/11/2025 resulting in direct beneficial ownership of 30,000 common shares of BridgeBio Oncology Therapeutics, Inc. (BBOT).

How many shares does John P. Schmid beneficially own after the reported transaction?

The filing shows 30,000 shares beneficially owned following the reported transaction, held directly.

Why were Helix Class B shares converted according to the Form 4?

The explanation states the conversion occurred in connection with a business combination and domestication that converted Helix Class B to Helix Class A one-for-one and then Class A shares into the Issuers common stock one-for-one.

Did John P. Schmid pay cash for the converted shares?

The Form 4 shows the conversion sequence and lists $0 in the derivative table for the price of the underlying shares, indicating no cash purchase price is reported for the conversion.

Did the reporting person change any roles at the company?

Yes. The filing states the reporting person was a director of Helix prior to the domestication and resigned effective 08/11/2025, immediately prior to the domestication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/11/2025 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schmid John P.

(Last) (First) (Middle)

C/O HELIX ACQUISITION CORP. II

200 CLARENDON STREET, 52ND FLOOR

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Former Director

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/11/2025		M(1)		30,000	A	(1)	30,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Class B ordinary shares	(1)	08/11/2025		M(1)			30,000	(1)	(1)	Class A ordinary shares	30,000	$0	0	D

Explanation of Responses:

1. In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date.

Remarks:

The Reporting person was a director of Helix prior to the Domestication and resigned from such role effective as of August 11, 2025, immediately prior to the Domestication.

	/s/ John P. Schmid	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.